94
Corti A, Ferrari R, Ceconi C (2000) Chromogranin A and tumor necrosis factor alpha in heart
failure. Chromogranins: Functional and Clinical Aspects (Advances in Experimental Medicine
and Biology) 482:351–359
Corti A, Mannarino C, Mazza R, Angelone T, Longhi R, Tota B (2004) Chromogranin A N-terminal
fragments vasostatin-1 and the synthetic CGA 7-57 peptide act as cardiostatins on the isolated
working frog heart. Gen Comp Endocrinol 136(2):217–224
Corti A, Pastorino F, Curnis F, Arap W, Ponzoni M, Pasqualini R (2011) Targeted drug delivery and
penetration into solid tumors. Med Res Rev. doi:10.1002/med.20238
Corti A, Curnis F, Rossoni G, Marcucci F, Gregorc V (2013) Peptide-mediated targeting of cyto-
kines to tumor vasculature: the NGR-hTNF example. BioDrugs 27(6):591–603. doi:10.1007/
s40259-013-0048-z
Courel M, Soler-Jover A, Rodriguez-Flores JL, Mahata SK, Elias S, Montero-Hadjadje M, Anouar
Y, Giuly RJ, O'Connor DT, Taupenot L (2010) Pro-hormone secretogranin II regulates dense
core secretory granule biogenesis in catecholaminergic cells. J Biol Chem 285(13):10030–
- doi:10.1074/jbc.M109.064196
Crippa L, Bianco M, Colombo B, Gasparri AM, Ferrero E, Loh YP, Curnis F, Corti A (2013) A new
chromogranin A-dependent angiogenic switch activated by thrombin. Blood 121(2):392–402.
doi:10.1182/blood-2012-05-430314
Curnis F, Sacchi A, Borgna L, Magni F, Gasparri A, Corti A (2000) Enhancement of tumor necro-
sis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopepti-
dase N (CD13). Nat Biotechnol 18(11):1185–1190
Curnis F, Sacchi A, Corti A (2002) Improving chemotherapeutic drug penetration in tumors by
vascular targeting and barrier alteration. J Clin Invest 110(4):475–482
Curnis F, Gasparri A, Longhi R, Colombo B, D’Alessio S, Pastorino F, Ponzoni M, Corti A (2012)
Chromogranin A binds to αvβ6-integrin and promotes wound healing in mice. Cell Mol Life
Sci 69(16):2791–2803
Deftos LJ (1991) Chromogranin A: its role in endocrine function and as an endocrine and neuro-
endocrine tumor marker. Endocr Rev 12(2):181–187
Di Comite G, Rossi CM, Marinosci A, Lolmede K, Baldissera E, Aiello P, Mueller RB, Herrmann
M, Voll RE, Rovere-Querini P, Sabbadini MG, Corti A, Manfredi AA (2009a) Circulating chro-
mogranin A reveals extra-articular involvement in patients with rheumatoid arthritis and curbs
TNF-alpha-elicited endothelial activation. J Leukoc Biol 85(1):81–87
Di Comite G, Previtali P, Rossi CM, Dell'Antonio G, Rovere-Querini P, Praderio L, Dagna L,
Corti A, Doglioni C, Maseri A, Sabbadini MG, Manfredi AA (2009b) High blood levels of
chromogranin A in giant cell arteritis identify patients refractory to corticosteroid treatment.
Ann Rheum Dis 68(2):293–295
Doblinger A, Becker A, Seidah NG, Laslop A (2003) Proteolytic processing of chromogranin A by
the prohormone convertase PC2. Regul Pept 111(1–3):111–116
Dondossola E, Gasparri A, Bachi A, Longhi R, Metz-Boutigue MH, Tota B, Helle KB, Curnis F,
Corti A (2010) Role of vasostatin-1 C-terminal region in fibroblast cell adhesion. Cell Mol Life
Sci 67(12):2107–2118. doi:10.1007/s00018-010-0319-5
Dondossola E, Gasparri AM, Colombo B, Sacchi A, Curnis F, Corti A (2011) Chromogranin A
restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic
efficacy. Cancer Res 71(17):5881–5890. doi:10.1158/0008-5472.CAN-11-1273
Dondossola E, Crippa L, Colombo B, Ferrero E, Corti A (2012) Chromogranin A regulates
tumor self-seeding and dissemination. Cancer Res 72(2):449–459. doi:10.1158/0008-5472.
CAN-11-2944
Eskeland NL, Zhou A, Dinh TQ, Wu H, Parmer RJ, Mains RE, O'Connor DT (1996) Chromogranin
A processing and secretion: specific role of endogenous and exogenous prohormone conver-
tases in the regulated secretory pathway. J Clin Invest 98(1):148–156
Ferrero E, Scabini S, Magni E, Foglieni C, Belloni D, Colombo B, Curnis F, Villa A, Ferrero ME,
Corti A (2004) Chromogranin A protects vessels against tumor necrosis factor alpha-induced
vascular leakage. FASEB J 18(3):554–555
F. Curnis et al.